Skip to content

Study · Observational study · n = 70 · 2026

10 results

Real-world effectiveness of oral semaglutide on body weight, composition, and metabolic parameters in patients with obesity without diabetes.

Nicolau J, Dotres K, Blanco-Anesto J

Medicina clinica21 Feb 2026

PMID41722140 (opens in a new tab)DOI10.1016/j.medcli.2026.107364 (opens in a new tab)PepBankPUB-41722140
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with obesity without diabetes, mean body weight decreased by 5.4 kg after 4 months of oral semaglutide.

    In plain wordsIn adults with obesity, body weight fell by 5.4 kg on average after 4 months of oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight change at 4 months
    Study

    n = 70

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    doses approved for type 2 diabetes · oral · 4 monthsAs given in this study (human).

    Measurements

    Body weight decrease
    5.4 kg
    4 months

    Source sentences

    Summary
    After 4 months, mean body weight decreased by 5.4kg
    2 context sentences
    Summary · context
    We conducted a multicenter, prospective, observational study including 70 adults with obesity without diabetes who initiated oral semaglutide as part of routine clinical care.
    Summary · context
    In real-world clinical practice, treatment with oral semaglutide at doses approved for type 2 diabetes was associated with short-term weight loss in patients with obesity, primarily driven by fat mass reduction, with preservation of muscle strength.
  2. 02HumanObservational studyEfficacy outcome

    In adults with obesity without diabetes, the weight loss on oral semaglutide was mainly due to a reduction in fat mass.

    In plain wordsIn adults with obesity, the weight lost on oral semaglutide came mainly from fat.

    Peptide
    Semaglutide
    Outcome
    DecreaseFat mass
    Study

    n = 70

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    doses approved for type 2 diabetes · oral · 4 monthsAs given in this study (human).

    Source sentences

    Summary
    mainly due to a reduction in fat mass
    2 context sentences
    Summary · context
    We conducted a multicenter, prospective, observational study including 70 adults with obesity without diabetes who initiated oral semaglutide as part of routine clinical care.
    Summary · context
    In real-world clinical practice, treatment with oral semaglutide at doses approved for type 2 diabetes was associated with short-term weight loss in patients with obesity, primarily driven by fat mass reduction, with preservation of muscle strength.
  3. 03HumanObservational studyEfficacy outcome

    In adults with obesity without diabetes, waist circumference decreased on oral semaglutide.

    In plain wordsIn adults with obesity, waist size fell on oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseWaist circumference
    Study

    n = 70

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    doses approved for type 2 diabetes · oral · 4 monthsAs given in this study (human).

    Source sentences

    Summary
    decreases in waist circumference
    2 context sentences
    Summary · context
    We conducted a multicenter, prospective, observational study including 70 adults with obesity without diabetes who initiated oral semaglutide as part of routine clinical care.
    Summary · context
    In real-world clinical practice, treatment with oral semaglutide at doses approved for type 2 diabetes was associated with short-term weight loss in patients with obesity, primarily driven by fat mass reduction, with preservation of muscle strength.
  4. 04HumanObservational studyEfficacy outcome

    In adults with obesity without diabetes, visceral fat decreased on oral semaglutide.

    In plain wordsIn adults with obesity, fat around the organs fell on oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseVisceral fat
    Study

    n = 70

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    doses approved for type 2 diabetes · oral · 4 monthsAs given in this study (human).

    Source sentences

    Summary
    and visceral fat.
    2 context sentences
    Summary · context
    We conducted a multicenter, prospective, observational study including 70 adults with obesity without diabetes who initiated oral semaglutide as part of routine clinical care.
    Summary · context
    In real-world clinical practice, treatment with oral semaglutide at doses approved for type 2 diabetes was associated with short-term weight loss in patients with obesity, primarily driven by fat mass reduction, with preservation of muscle strength.
  5. 05HumanObservational studyEfficacy outcome

    In adults with obesity without diabetes, lean mass showed a small reduction on oral semaglutide.

    In plain wordsIn adults with obesity, lean body mass fell a little on oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseLean mass
    Study

    n = 70

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    doses approved for type 2 diabetes · oral · 4 monthsAs given in this study (human).

    Source sentences

    Summary
    Lean mass showed a small reduction
    2 context sentences
    Summary · context
    We conducted a multicenter, prospective, observational study including 70 adults with obesity without diabetes who initiated oral semaglutide as part of routine clinical care.
    Summary · context
    In real-world clinical practice, treatment with oral semaglutide at doses approved for type 2 diabetes was associated with short-term weight loss in patients with obesity, primarily driven by fat mass reduction, with preservation of muscle strength.
  6. 06HumanObservational studyEfficacy outcome

    In adults with obesity without diabetes, muscle strength remained unchanged on oral semaglutide.

    In plain wordsIn adults with obesity, muscle strength did not change on oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    No significant changeMuscle strength
    Study

    n = 70

    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    doses approved for type 2 diabetes · oral · 4 monthsAs given in this study (human).

    Source sentences

    Summary
    while muscle strength remained unchanged.
    2 context sentences
    Summary · context
    We conducted a multicenter, prospective, observational study including 70 adults with obesity without diabetes who initiated oral semaglutide as part of routine clinical care.
    Summary · context
    In real-world clinical practice, treatment with oral semaglutide at doses approved for type 2 diabetes was associated with short-term weight loss in patients with obesity, primarily driven by fat mass reduction, with preservation of muscle strength.
  7. 07HumanObservational studyEfficacy outcome

    In adults with obesity without diabetes, clinically meaningful weight loss was achieved by 44.3% of patients on oral semaglutide.

    In plain wordsIn adults with obesity, 44.3% of people reached a clinically meaningful weight loss on oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    Not applicableClinically meaningful weight loss
    Study

    n = 70

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    doses approved for type 2 diabetes · oral · 4 monthsAs given in this study (human).

    Measurements

    Responders with clinically meaningful weight loss
    44.3%
    4 months

    Source sentences

    Summary
    Clinically meaningful weight loss was achieved by 44.3% of patients.
    2 context sentences
    Summary · context
    We conducted a multicenter, prospective, observational study including 70 adults with obesity without diabetes who initiated oral semaglutide as part of routine clinical care.
    Summary · context
    In real-world clinical practice, treatment with oral semaglutide at doses approved for type 2 diabetes was associated with short-term weight loss in patients with obesity, primarily driven by fat mass reduction, with preservation of muscle strength.
  8. 08HumanObservational studyEfficacy outcome

    In adults with obesity without diabetes, improvements in metabolic parameters were observed on oral semaglutide.

    In plain wordsIn adults with obesity, metabolic measures improved on oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedMetabolic parameters
    Study

    n = 70

    Outcome group
    Metabolic pathways and metabolomics · Metabolic and weight
    Studied dose
    doses approved for type 2 diabetes · oral · 4 monthsAs given in this study (human).

    Source sentences

    Summary
    Improvements were also observed in metabolic parameters, inflammatory markers, and depressive symptoms.
    2 context sentences
    Summary · context
    We conducted a multicenter, prospective, observational study including 70 adults with obesity without diabetes who initiated oral semaglutide as part of routine clinical care.
    Summary · context
    In real-world clinical practice, treatment with oral semaglutide at doses approved for type 2 diabetes was associated with short-term weight loss in patients with obesity, primarily driven by fat mass reduction, with preservation of muscle strength.
  9. 09HumanObservational studyEfficacy outcome

    In adults with obesity without diabetes, improvements in inflammatory markers were observed on oral semaglutide.

    In plain wordsIn adults with obesity, markers of inflammation improved on oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedInflammatory markers
    Study

    n = 70

    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    doses approved for type 2 diabetes · oral · 4 monthsAs given in this study (human).

    Source sentences

    Summary
    Improvements were also observed in metabolic parameters, inflammatory markers, and depressive symptoms.
    2 context sentences
    Summary · context
    We conducted a multicenter, prospective, observational study including 70 adults with obesity without diabetes who initiated oral semaglutide as part of routine clinical care.
    Summary · context
    In real-world clinical practice, treatment with oral semaglutide at doses approved for type 2 diabetes was associated with short-term weight loss in patients with obesity, primarily driven by fat mass reduction, with preservation of muscle strength.
  10. 10HumanObservational studyEfficacy outcome

    In adults with obesity without diabetes, improvements in depressive symptoms were observed on oral semaglutide.

    In plain wordsIn adults with obesity, depressive symptoms improved on oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedDepressive symptoms
    Study

    n = 70

    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    doses approved for type 2 diabetes · oral · 4 monthsAs given in this study (human).

    Source sentences

    Summary
    Improvements were also observed in metabolic parameters, inflammatory markers, and depressive symptoms.
    2 context sentences
    Summary · context
    We conducted a multicenter, prospective, observational study including 70 adults with obesity without diabetes who initiated oral semaglutide as part of routine clinical care.
    Summary · context
    In real-world clinical practice, treatment with oral semaglutide at doses approved for type 2 diabetes was associated with short-term weight loss in patients with obesity, primarily driven by fat mass reduction, with preservation of muscle strength.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.